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Available online 12 January 2016Background: The clinical signiﬁcance of excessively high serumNT-proBNP is poorly understood in chronic heart
failure (HF).
Methods:One-hundred eighteen patients with advanced chronic HF (NYHA functional class III or IV)were admit-
ted; of these patients, 42.4% exhibited NT-proBNP levels N10,000 pg/ml. The patients were divided into three
groups as follows: ≥400 and b10,000 pg/ml, group I (n = 68); ≥10,000 and b20,000 pg/ml, group II (n = 28);
and ≥20,000 pg/ml, group III (n = 22). The determinants of elevated NT-proBNP levels and responsiveness to
HF medications were compared among these groups. A subgroup of HF patients with normal serum creatinine
was analyzed separately.
Results:Overall, cardiac, renal and laboratory parameters (serum creatinine, potassium and uric acid, positively; and
eGFR and hemoglobin, negatively) correlated with serum NT-proBNP levels. In patients with normal serum creati-
nine, left ventricular ejection fraction, serum potassium and hemoglobin correlated with serum NT-proBNP levels.
In-hospital mortality was higher in patients with the highest NT-proBNP levels. After successful HF treatment, the
patients in each group lost body weight and improved to NYHA class I or II, and NT-proBNP levels were halved,
irrespective of their baseline levels. Excessively high NT-proBNP levels were related to cardiac, renal and laboratory
abnormalities; therefore, the role and underlying mechanism of high NT-proBNP levels must be studied further.
Conclusion: Excessively high NT-proBNP levels in HF patients correlated with cardiac, renal and laboratory parame-
ters. After successful HF treatment, NT-proBNP levels were halved, irrespective of their baseline levels. The precise
role and underlying mechanism of NT-proBNP warrant further study.Tach
r, Re
wa).
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The prevalence of chronic heart failure (HF) is increasing in many
developed countries. Both bioactive brain-type natriuretic peptide
(BNP) and an inactive marker molecule (NT-proBNP), which is derived
from the BNP precursor [1–4] have been used for the diagnosis and
pharmacological management of HF [5,6].
BNP clearance occurs in the kidney, liver, and vascular endothelium
through clearance receptor and neutral endopeptidase [7], whereas NT-
proBNP is believed to be cleared solely in the kidney through unknown
mechanism [1,8].ikawa Medical Center for
search and Development,
Ltd. This is an open access articlBecause NT-proBNP has some advantages over BNP, including
higher circulating levels and superior stability, and only a small amount
of serum is required for its measurement [9–11], we used NT-proBNP
for the diagnosis and evaluation of HF severity in this study.
However, it is not uncommon to encounter patients with advanced
HF who present with excessively high levels of NT-proBNP, i.e.,
N10,000–30,000 pg/ml. In such patients, the determinants of cardiac
peptide levels and their responsiveness to intensiﬁed HF therapy are
poorly understood.2. Patients and methods
Between April 2012 and March 2014, 118 adults were admitted to
our hospital for decompensated chronic HF. They had been treated by
cardiologists at the outpatient clinic, according to the guideline for HF
treatment [12,13]. At the time of admission, all patients exhibitede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patients’ clinical characteristics.
Group I
(n = 68)
Group II
(n = 28)
Group III
(n = 22)
I vs. II/I vs. III
Age (yrs.) 76.7 ± 11.7 73.9 ± 25.1 82.9 ± 8.3 0.06/0.024
Male, n (%) 48 (72.7) 20 (71.4) 16 (72.7) 0.934/0.395
No. of admissions 1.7 ± 1.3 2.7 ± 1.8 1.7 ± 1.1 0.031/0.829
Ejection fraction (%) 47.5 ± 15.8 38.9 ± 14.6 39.4 ± 16.6 0.015/0.048
LVDD (mm) 52.5 ± 10.0 53.6 ± 7.6 56.0 ± 13.2 0.616/0.208
Pleural effusion 39 (57.4%) 20(71.4) 20(100.0) 0.040/0.030
UDH, n (%)
Ischemic HD 27(39.7) 11 (39.3) 9 (40.9) 0.970/0.673
Valvular HD 42(61.8) 17(60.7) 18 (81.8) 1.000/0.017
Non-ischemic CM 10 (14.7) 5(17.9) 7 (31.8) 0.702/0.448
Hypertension 53(77.9) 24 (85.7) 13 (59.1) 0.526/0.938
Diabetes mellitus 21(30.9) 7(25.0) 6(27.3) 0.561/0.940
Dyslipidemia 18 (26.5) 7 (25.0) 7 (31.8) 0.561/0.744
CKD 46(67.6) 25(89.3) 20(100.0) 0.020/b0.001
AF/FL 39 (57.4) 12 (42.9) 10 (45.5) 0.198/0.562
VT 3 (4.4) 0 1 (4.5) 1.000/0.913
Miscellaneous 3 (4.4) 2(7.1) 3 (13.6) 0.595/0.129
Medication, n (%)
ACEI/ARB 39 (57.4) 12 (42.9) 12 (54.5) 0.255/0.833
Beta-blockers 16 (23.5) 11 (39.3) 9 (40.9) 0.125/0.069
Diuretics 60 (88.2) 28(100.0) 25 (100.0) 0.058/0.108
Anti-aldosterone 16 (23.5) 8(14.3) 7 (31.8) 0.607/0.315
CCB 34(50.0) 11(39.3) 9(40.9) 0.276/0.610
Digoxin 13 (19.1) 5 (17.9) 4 (18.2) 0.885/0.930
AA 34 (50.0) 9 (32.1) 7 (31.8) 0.082/0.192
AA: antiarrhythmic agent. AF/FL: atrial ﬁbrillation/ﬂutter. CCBs: calcium channel blockers.
CKD: chronic renal disease. CM: cardiomyopathy. HD: heart disease. LVDD: Left ventricu-
lar diastolic dimension. VT: ventricular tachycardia. UDH: underlying heart disease.
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ﬁed HF treatment was attempted.
The exclusion criteria were as follows: the performance or the plan-
ning of an urgent invasive or surgical intervention during admission, se-
vere chronic obstructive pulmonary disease or pulmonary embolism
less than 3 months prior to admission, and pulmonary hypertension
not caused by left ventricular systolic dysfunction. Patients with mitral
regurgitation of more than moderate severity secondary to ischemic
or non-ischemic cardiomyopathy, patients with valvular heart disease
and patients on chronic hemodialysis or peritoneal dialysis were also
excluded.
2.1. Management during hospitalization
After physical examination of patients, a blood sample was drawn to
collect laboratory data, including an NT-proBNP level; lab test were
measured (using the ECLIA method) after admission and before dis-
charge. An ECG, chest X-ray and echocardiogram were performed. The
estimated glomerular ﬁltration rate (eGFR) was calculated using a re-
vised equation for Japanese people, and chronic kidney disease (CKD)
was deﬁned as an eGFR b60 ml/min/1.73 m2 [14].
After admission, patients were maintained on bed-rest. Both ﬂuid
and salt intake were controlled, and diuresis was facilitated via either
loop diuretics alone or in combination with ANP [15] until symptoms
of congestion resolved. HF medication dosages were increased or de-
creased when necessary, and additional medications were utilized for
speciﬁc patients as tolerated. Patients suffering from tachycardic atrial
ﬁbrillation received either verapamil or a beta-blocker to maintain a
ventricular rate of less than 100 beats per minute. The clinical end-
points were the resolution of peripheral edema and pulmonary conges-
tion, as well as other symptoms, and patients were discharged in NYHA
class I or II.
2.2. Data analysis
Baseline patient clinical data were analyzed and the correlations be-
tween laboratory parameters and NT-proBNP levels were analyzed. The
patients were then divided into three groups according to their basal
NT-proBNP levels as follows: group I, with an NT-proBNP level ≥400
and b10,000 pg/ml; group II, with an NT-proBNP level ≥10,000 and
b20,000 pg/ml; and group III, with an NT-proBNP ≥20,000 pg/ml. Base-
line patient clinical data were compared among the three groups, and
the correlations between laboratory data and NT-proBNP levels were
analyzed. Underlying heart diseases, comorbidities and medications
were also compared among the subgroups. To minimize the effect of
renal dysfunction on cardiac peptide levels, a similar analysis was per-
formed in patients with serum creatinine levels b0.1 mg/dl.
The post-hospital courses of the three groups were compared to
evaluate their outcomes after discharge. Finally, changes in body
weight, NYHA functional class, and serum NT-proBNP levels as well as
signs and symptoms of HF, were compared among the three groups,
for the patients who remained alive and discharged.
2.3. Statistical analysis
Continuous data are presented as the means ± standard deviations
(SD), and the categorical variables are expressed as either absolute
numbers or percentages. Statistical comparisons between groups were
made using either the t-test or ANOVA for continuous variables or
Pearson's chi-squared test for categorical variables. JMP software (Sta-
tistical Discovery Software, version 5.0.1 J, SAS Institute, Cary, NC,
USA) was used to perform the statistical analysis. A two-sided test
with P b 0.05 was considered statistically signiﬁcant.
This retrospective case study was conducted according to the guide-
lines of clinical research in Japan and was approved by the Institutional
Review Board of Tachikawa Medical Center.3. Results
3.1. Clinical features on admission
All patients exhibited symptoms characteristic of NYHA functional
classes III-IV upon admission. These clinical characteristics are shown
in Table 1. The majority of patients (N70%) were male. Sixty-eight pa-
tients belonged to group I; 28, to group II; and 20, to group III (Table 1).
The mean age of group I was younger than that of the other two
groups. The number of previous hospitalizations for HF was higher
among the patients in group II than group I: 2.7 ± 1.8 vs. 1.7 ± 1.3 hos-
pitalization (P = 0.082). The prevalence of pleural effusions was lower
in group I than in the other two groups. The left ventricle was more di-
lated as NT-proBNP increased, and ejection fractionwas signiﬁcantly re-
duced in groups II and III compared with group I.
Therewere no signiﬁcant differences in the prevalence of underlying
heart disease and comorbidities, with the exception of valvular heart
diseases, which was most prevalent in group III. CKD and dyslipidemia
were more frequent in groups II and III than in group I. Otherwise,
there were no signiﬁcant differences in comorbidities or medications
prior to hospitalization (Table 1).
As NT-proBNP increased, serum potassium, creatinine and uric acid
increased, and eGFR and hemoglobin (Hb) decreased. AST and white
blood cells (WBC) levels were higher in group III than group I (Table 2).
3.2. Correlation between laboratory parameters and NT-proBNP
Overall, signiﬁcant correlations were observed between age, serum
creatinine, ejection fraction, diastolic left ventricular diameter, Hb,
serum potassium, uric acid and WBC and NT-proBNP (Fig. 1, Table 3).
Among the 3 subgroups, signiﬁcant correlations were observed in
these parameters: between NT-proBNP levels and serum creatinine in
group I, NT-proBNP andWBC in group II and NT-proBNP and serum cre-
atinine in group III.
The relationship betweenNT-proBNP levels and other laboratory pa-
rameters was evaluated separately in 50 patients with preserved renal
function. In this subgroup, all patients had a normal serum creatinine:
Table 2
Laboratory ﬁndings among the three patient groups.
Group I
(n = 68)
Group II
(n = 28)
Group III
(n = 22)
P value
I vs. II/I vs. III
Na (mEq/l) 140.0 ± 4.0 139.2 ± 3.8 139.1 ± 4.1 0.273/0.453
K (mEq/l) 4.2 ± 0.6 4.4 ± 0.5 4.8 ± 0.8 0.176/b0.001
Cl (mEq/l) 104.2 ± 4.7 104.7 ± 5.4 105.5 ± 4.7 0.929/0.254
WBC (μl) 7176 ± 3807 7617 ± 3134 10,337 ± 7090 0.589/0.009
CRP (mg/dl) 2.26 ± 4.58 2.04 ± 2.06 3.25 ± 3.21 0.818/0.361
Hb (g/dl) 12.1 ± 2.6 10.7 ± 2.0 9.8 ± 2.4 0.008/b0.001
s-Cre (mg/dl) 1.22 ± 0.58 1.61 ± 0.96 2.20 ± 1.82 0.018/b0.001
eGFR 38.5 ± 26.5 45.5 ± 30.4 28.7 ± 19.8 0.544/b0.001
AST (U/l) 93.0 ± 452a 44.0 ± 23.4 108.0 ± 203.0 0.348/0.007
ALT (U/l) 57.6 ± 224.2 35.1 ± 26.0 62.0 ± 105.8 0.599/0.931
T-Bil (mg/dl) 0.86 ± 0.46 0.82 ± 0.43 0.9 ± 0.6 0.776/0.984
TP (g/dl) 6.3 ± 0.8 6.37 ± 0.60 6.53 ± 0.78 0.836/0.351
UA (mg/dl) 6.7 ± 1.8 7.2 ± 2.0 9.3 ± 3.2 0.298/b0.001
ALT: alanine aminotransferase. AST: aspartate aminotransferase. CRP: C-reactive protein.
Hb: hemoglobin. eGFR: ml/min/1.73 m2. s-Cre: serum creatinine. T-Bil: total bilirubin.
TP: total protein. UA: serum uric acid.
a One patient had high AST level: 3700 U/l.
Table 3
Correlations between laboratory data and serum NT-proBNP levels.
All Group I Group II Group III
Age – – – –
S-CR r = 0.24 (0.009) r = 0.39 (0.001) – r = 0.55 (0.009)
eGFR r = 0.21 (0.025) r = 0.28 (0.023) – –
LVDD r = 0.19 (0.040) – – –
EF r = 0.33 (b0.001) – – –
Hb r = 0.28 (0.003) – – –
K r = 0.28 (0.003) – – –
UA r = 0.40 (b0.001) – – –
WBC r = 0.26 (0.005) r = 0.26 (0.035) r = 0.40 (0.035) –
AST r = 0.26 (0.005) – – –
Abbreviations are the same in Tables 1 and 2.
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the NT-proBNP levels was 9032 ± 9490 pg/ml with a range from
789 pg/ml to 34,739 pg/ml. The ejection fraction signiﬁcantly correlated
with NT-proBNP (r = 0.32, P = 0.002), whereas the left ventricular di-
mension did not (r = 0.03, P = 0.825). Signiﬁcant correlations were
found between NT-proBNP and serum potassium (r = 0.50, P b 0.001)
and NT-proBNP and hemoglobin (r = 0.41, P = 0.003).3.3. Courses after hospitalization
In addition to bed-rest and restricted salt intake, patients received
loop diuretics, bothwith andwithout intravenous atrial natriuretic pep-
tide. Either an ARB orACEIwas initiated in 8 patients (4, 1 and 3 patientsFig. 1. The correlations between NT-pro BNP levels and cardiac or renal parameters. Serum N
ventricular dimension (LVDD), serum creatinine (s-CR) and estimated glomerular ﬁltratio
evidence of congestion. Correlations between age and laboratory parameters with NT-proBNPin groups I, II and III, respectively), and dosageswere intensiﬁed in 7 pa-
tients (4, 1 and 2 patients in groups I, II and III, respectively). In 9 pa-
tients (3 patients in each group), the dose of either an ARB or an
ACEI was reduced because of either low blood pressure or increased
serum potassium. Beta blocker treatments were initiated in 12 patients
(10, 1 and 1 patients in groups I, II and III), and the dosages were
increased in 2 patients in group II and decreased in 4 patients and 1 pa-
tient in groups I and III, respectively. Aldosterone antagonist treatments
were initiated in 11 patients (7, 3 and 1 patient in groups I, II and III),
and dosageswere decreased in 12 patients (5, 3 and 4 patients in groups
I, II and III) due to increased serum potassium levels or renal
dysfunction.
Another diuretic was administered to 18 patients (13, 2 and 3 pa-
tients in groups I, II and III); diuretic dosages were increased in 20 pa-
tients (14, 5 and 1 patients). Loop diuretic dosages were decreased in
18 patients (11, 5 and 2 patents in groups I, II and III) to prevent
hyponatremia. Abnormal CRP levels and WBCs normalized both with
and without the use of antibiotics, and AST and ALT levels also normal-
ized within a week without speciﬁc treatment.T-proBNP levels were weakly but signiﬁcantly correlated with ejection fraction (EF), left
n rate (e-GFR). All patients were within NYHA functional class III or IV and exhibited
are summarized in Table 3.
Fig. 2. Changes in body weight, NYHA functional class and NT-proBNP. Upon discharge, patients in each group lost body weight from 4.2–4.6 kg (P b 0.001) of body weight. The NYHA
functional class was reduced to less than II (P b 0.001), and the NT-proBNP levels decreased to half of their baseline (P b 0.001). Means with one SD are shown at the time of
admission and discharge.
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Of the 118 patients included in this study, 11 patients died during
their hospitalizations from HF, including 3 patients (4.4%) in group I, 1
patient (3.6%) in group II and 7 patients (35%) in group III; themortality
rate was signiﬁcantly higher in group III than group 1 (P b 0.001) or
group II (P = 0.04). Mean age and NT-proBNP levels were higher
among the patients who died compared with those who were
discharged alive as follows: 88.4 ± 5.7 years vs. 77.8 ± 10.9 years
(P b 0.001) and 22,186 ± 11,977 pg/ml vs. 9602 ± 11,537 pg/ml
(P b 0.001), respectively.
The 107 patients discharged alivewere in NYHA class II or I. The hos-
pitalization durations were 27 ± 18 days, 29 ± 19 days and 43 ±
45 days in groups I, II and III, respectively, and the duration was signiﬁ-
cantly longer in group III than group I (P= 0.0185). Patients lost an av-
erage of 4.6 ± 3.6 kg, 4.3 ± 3.5 kg and 4.2 ± 3.2 kg of body weight in
groups I, II and III, respectively (no signiﬁcant difference) by the time
of discharge. NT-proBNP levels were reduced by 46.9 ± 36.1%, 56.5 ±
29.4% and 43.2 ± 38.1%, in groups I, II and III, respectively; the differ-
ences among the three groups were not signiﬁcant (P = 0.3988–
0.7520, Fig. 2).
During the two year follow up after discharge, 12 patients died, in-
cluding 5 (7.7%), 4 (14.8%) and 3 (23.1%) patients in groups I, II and III,
respectively, and 32 patients were readmitted, including 19 (29.2%), 8
(29.6%) and 5 (38.5%) patients in groups I, II and III, respectively.
There were no signiﬁcant differences in the mortality or readmission
rates among the three groups after discharge.4. Discussion
NT-proBNP levels N10,000 pg/mlwere found in 42.4% of ambulatory
HF patientswhowere admitted to our hospital inNYHA class III or IV. As
NT-proBNP levels increased, the left ventricle becamemore dilated, and
serum potassium, creatinine, WBC, and uric acid became elevated,
whereas eGFR and hemoglobin decreased. Although the association
was weak, NT-proBNP levels signiﬁcantly correlated with these param-
eters. In patients with normal renal function, NT-proBNP levels correlat-
ed with ejection fraction.Patients with higher NT-proBNP levels upon admission were at
higher risk for in-hospital mortality. The patients discharged alive
were all in NYHA functional class I or II, and their signs and symptoms
of congestion has resolved. At discharge, NT-proBNP levels had de-
creased to a half of their baseline values. For patients with excessively
high NT-proBNP levels, the cardiac peptide may be a marker of the se-
verity of HF; treating HF until the initial NT-proBNP level is halved
could be an endpoint of intensiﬁed HF therapy. However, the determi-
nants of serum NT-proBNP in advanced HF patients are still not fully
understood.
4.1. NT-proBNP in HF
NT-proBNPmay be the preferred laboratory parameter for some cli-
nicians for guiding HF treatment [10,16–22]. In themajority of previous
studies [10,16–21], baseline NT-proBNP levels ranged from 3000 to
5000 pg/ml, and the target cardiac peptide level for treatment was set
at either a predetermined target or the lowest level [10,13,16–21]. How-
ever, there are many patients who exhibit very high NT-proBNP levels;
approximately 40% of the patients enrolled in this study exhibited NT-
proBNP levels N10,000 pg/ml. In patients who present with excessively
high serum NT-proBNP, it would be unrealistic to expect their levels
to normalize. As a target of intensiﬁed HF therapy, a reduction in NT-
proBNP to half of its baseline level seems realistic, irrespective of the
baseline level (Fig. 2). However, other factorsmay also affect or mod-
ulate serum NT-proBNP levels in advanced HF patients. The determi-
nants and dynamics of NT-proBNP during HF treatment require
further study.
4.2. Changes in NT-proBNP during HF treatment
The major determinants of serum NT-proBNP levels are the release
of the peptide from the heart and the clearance and/or degradation of
the peptide by the kidney. In acute HF, the heart is exposed to increased
wall stress and the release of proBNP is increased; it has been demon-
strated that NT-proBNP levels correlate well with hemodynamic alter-
ations [23].
In the present study, left ventricular ejection fraction decreased as
NT-proBNP increased (Table 1). A signiﬁcant correlation between
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the conclusion that the latter is a determinant of cardiac peptide levels
(Fig. 1, Table 3). When the effect of renal dysfunction was minimized
by analyzing only patients with normal renal function (serum
creatinine b 0.1 mg/dl), a signiﬁcant correlation was observed between
left ventricular ejection fraction and NT-proBNP. A relatively weak cor-
relation, however, may suggest the presence of other determinants of
excessively high NT-proBNP levels.
NT-proBNP is eliminated from the kidneys by clearance and/or deg-
radation, but the precise mechanism underlying this phenomenon has
not yet been clariﬁed [7,8,24–27]. As serum creatinine increased (and
eGFR decreased), NT-proBNP increased, and a signiﬁcant correlation
was observed between serum creatinine and NT-proBNP (Fig. 1,
Tables 2 and 3).
By the time of discharge, all patients were free from symptoms and
signs of congestive HF and had lost an average of 4.2 to 4.6 kg of body
weight. The reduction in bodyweight represented the removal of excess
body ﬂuid. When decompensated HF improved, serum NT-proBNP
levels decreased to approximately half of their baseline levels, irrespec-
tive of these baseline levels.
It is likely that the fall of serumNT-proBNPwas induced by themajor
two mechanisms: a reduction in the release of the cardiac peptide from
heart and augmented clearance or degradation by the kidney, but other
factorsmust be involved to account for the excessively high levels of the
peptide observed in this study and elsewhere.
Several parameters correlated with NT-proBNP levels: serum potas-
sium, uric acid, hemoglobin, AST and WBC. Some of these parameters
reﬂect impaired renal function, whereas others may affect NT-proBNP
dynamics in an unknown way. After the intensiﬁcation of HF medica-
tion therapy during the hospitalization, large changes in NT-proBNP
levels were observed in each patient in conjunction with resolution of
HF signs and symptoms, even among the patients with excessively
high baseline levels of the peptide.
4.3. Limitations
This study treated a relatively small number of patients suffering
from advanced HF secondary to heterogeneous underlying heart dis-
eases. Most patients had multiple comorbidities. The study did not in-
clude pressure readings from the ventricles or the pulmonary artery,
and NT-proBNP or its degraded products were not measured in the
urine. The relationship betweenHF improvement andNT-ProBNP levels
warrants further study in advanced HF patients. However, a similar de-
crease in NT-proBNP levels occurred irrespective of baseline values after
the successful intensiﬁcation of HF therapy, and these ﬁndings are not
likely to be coincidental phenomena.
5. Conclusion
In our study, patients with advanced HF (NYHA class III or IV) exhib-
ited excessively high levels of NT-proBNP on admission. Cardiac, renal
and some laboratory parameters correlated with the NT-proBNP levels.
Irrespective of their baseline values, NT-pro-BNP levels were halved by
intensiﬁed HF treatment, and the signs and symptoms of HF were suc-
cessfully improved to NYHA II or I. The determinants and the mecha-
nisms regulating NT-proBNP dynamics warrant further study.
6. Clinical perspectives
Excessively high NT-proBNP levels of 10,000 pg/ml or higher can be
observed in advanced heart failure patients. In our study, patients were
admitted in NYHA class III or IV HF. In our sample, a signiﬁcant but weak
correlation was observed between cardiac or renal function and other
laboratory parameters and NT-proBNP. In patients with preserved
renal function (serum creatinine b 1.0 mg/dl), NT-proBNP levels signif-
icantly correlated with ejection fraction, but not with left ventriculardimension. The determinants and the mechanisms underlying the dy-
namic response of NT-proBNP must be examined in advanced HF pa-
tients. Higher NT-proBNP levels were associated with increased in-
hospital mortality. When patients improved to NYHA functional class I
or II with intensiﬁed medication therapy, the NT-proBNP levels de-
creased to a half of their baseline levels, irrespective of the initial levels.
Such a fall in NT-proBNP could be a marker of a therapeutic endpoint in
the treatment of advanced heart failure.
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